keyword
MENU ▼
Read by QxMD icon Read
search

capecitabine

keyword
https://www.readbyqxmd.com/read/28102094/tolerability-of-the-oral-fluoropyrimidine-s-1-after-hand-foot-syndrome-related-discontinuation-of-capecitabine-in-western-cancer-patients
#1
J J M Kwakman, A Baars, H Boot, J F M Pruijt, S B Winther, P Pfeiffer, C J A Punt
No abstract text is available yet for this article.
January 19, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28101757/final-report-of-kscc0803-feasibility-study-of-capecitabine-as-adjuvant-chemotherapy-for-stage-iii-colon-cancer-in-japan
#2
Kazuhito Minami, Masaru Morita, Yasunori Emi, Masahiro Okamoto, Eiji Tanaka, Shigeyuki Nagata, Tetsuo Touyama, Kippei Ohgaki, Takaho Tanaka, Hiroshi Okumura, Toyokuni Suenaga, Shoji Tokunaga, Eiji Oki, Yoshihiro Kakeji, Yoshito Akagi, Hideo Baba, Shoji Natsugoe, Yoshihiko Maehara
BACKGROUND: The impact of oral capecitabine as adjuvant chemotherapy for Japanese patients with resected colon cancer was unclear. We previously planned and conducted a prospective feasibility study (KSCC0803) and reported on the safety of oral capecitabine as adjuvant chemotherapy for Japanese patients with resected stage III colon cancer. The purpose of the current study was to assess the survival results from that study. METHODS: The study subjects were Japanese patients with resected stage III colon cancer...
January 18, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28099947/short-term-efficacy-of-different-chemotherapy-regimens-in-the-treatment-of-advanced-gastric-cancer-a-network-meta-analysis
#3
Mi-Ma Duo-Ji, Ba-Sang Ci-Ren, Zi-Wen Long, Xiao-Hua Zhang, Dong-Lin Luo
OBJECTIVE: A network meta-analysis was performed to compare the short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer. METHODS: Randomized controlled trials of different chemotherapy regimens for advanced gastric cancer were included in this study. Network meta-analysis combined direct evidence and indirect evidence to evaluate the odds ratio and draw surface under the cumulative ranking curves of different chemotherapy regimens in advanced gastric cancer...
January 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28095397/a-randomised-phase-ii-trial-and-feasibility-study-of-palliative-chemotherapy-in-frail-or-elderly-patients-with-advanced-gastroesophageal-cancer-321go
#4
P S Hall, S R Lord, M Collinson, H Marshall, M Jones, C Lowe, H Howard, D Swinson, G Velikova, A Anthoney, R Roy, J Dent, S Cheeseman, K Last, M T Seymour
BACKGROUND: Elderly patients are commonly under-represented in cancer clinical trials. The 321GO was undertaken in preparation for a definitive phase three trial assessing different chemotherapy regimens in a frail and/or elderly population with advanced gastroesophageal (GO) cancer. METHODS: Patients with advanced GO cancer considered unfit for conventional dose chemotherapy were randomly assigned in a 1 : 1 : 1 ratio to: epirubicin, oxaliplatin and capecitabine (EOX); oxaliplatin and capecitabine (OX); and capecitabine alone (X) (all 80% of full dose and unblinded)...
January 17, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28088627/the-telomere-binding-protein-trf2-is-required-for-metronomic-therapeutic-effects-of-gemcitabine-and-capecitabine
#5
Wei-Ping Lee, Keng-Hsin Lan, Chung-Pin Li, Yee Chao, Ming-Chih Hou, Han-Chieh Lin, Shou-Dong Lee
Gemcitabine and capecitabine are two effective anticancer agents against solid tumors. The pharmacological mechanisms have been known as incorporation into DNA and thereby inhibition of DNA synthesis. When used as metronomic chemotherapy, they may inhibit angiogenesis and induce immunity. In our previous study, we showed that low-dose gemcitabine caused telomere shortening by stabilizing TRF2 that was required for XPF-dependent telomere loss. In this report, we established a SKOV3.ip1 ascites cell model. Tumor-bearing mice were treated with low-dose gemcitabine (GEM) or capecitabine (CAP)...
January 11, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28079003/colorectal-cancer-chemotherapy-the-evolution-of-treatment-and-new-approaches
#6
Rachel M McQuade, Vanesa Stojanovska, Joel C Bornstein, Kulmira Nurgali
Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality. Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above 60%, more than 50% of patients are diagnosed at or beyond stage III when distant metastasis has already occurred, in which case 5 year survival rate drops to 10%. Chemotherapeutic intervention coupled with surgery is the backbone of metastatic CRC treatment and the only means of enhanced survival. For decades following its discovery, an antimetabolite 5-fluorouracil (5-FU) was the only chemotherapeutic agent available to successfully improve 12 month survival in CRC patients...
January 11, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28078540/preplanned-safety-analysis-of-the-jfmc37-0801-trial-a-randomized-phase-iii-study-of-six-months-versus-twelve-months-of-capecitabine-as-adjuvant-chemotherapy-for-stage-iii-colon-cancer
#7
Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko, Ken Kondo, Hideyuki Ishida, Genichi Nishimura, Kazuaki Sasaki, Takayuki Morita, Shoichi Hazama, Koutarou Maeda, Hideyuki Mishima, Hideyuki Ike, Sotaro Sadahiro, Kenichi Sugihara, Masazumi Okajima, Shigetoyo Saji, Junichi Sakamoto, Naohiro Tomita
BACKGROUND: Six months of adjuvant chemotherapy is regarded as the standard of care for patients with stage III colon cancer. However, whether longer treatment can improve prognosis has not been fully investigated. We conducted a phase III study comparing 6 and 12 months of adjuvant capecitabine chemotherapy for stage III colon cancer, and report here the results of our preplanned safety analysis. METHODS: Patients aged 20-79 years with curatively resected stage III colon cancer were randomly assigned to receive 8 cycles (6 months) or 16 cycles (12 months) of capecitabine (2500 mg/m(2)/day on days 1-14 of each 21-day cycle)...
January 11, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28078119/surgical-outcomes-of-post-chemoradiotherapy-unresectable-locally-advanced-rectal-cancers-improve-with-interim-chemotherapy-is-folfirinox-better-than-capox
#8
Vikas Ostwal, Reena Engineer, Anant Ramaswamy, Arvind Sahu, Saurabh Zanwar, Suprita Arya, Supriya Chopra, Munita Bal, Prachi Patil, Ashwin Desouza, Avanish Saklani
BACKGROUND: Role of chemotherapy in patients who continue to have unresectable disease after pre-operative chemo-radiotherapy (CRT) remains largely unaddressed. METHODS: Patients with LA rectal cancer from January 2013 to June 2015 were evaluated. Post-CRT, patients, who were deemed unresectable, were considered for further interim chemotherapy (i-CT). RESULTS: Seventy six patients (15%) with median age of 38.5 years received i-CT after CRT...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28074721/-capecitabine-induced-ventricular-fibrillation
#9
A V van Capelle, J de Valk, D Schakenraad, T Germans, D Ten Oever
BACKGROUND: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of colorectal, gastric and breast carcinoma. Capecitabine has relatively mild side effects. Less known are its potential severe cardiotoxic effects. CASE DESCRIPTION: We report a case of a 61-year-old man recently diagnosed with rectal cancer. Six days after starting with capecitabine, he developed a cardiac arrest due to ventricular fibrillation (VF). Extensive additional diagnostics did not explain the cardiac arrest nor VF...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/28072706/a-randomized-multicenter-phase-iii-study-of-gemcitabine-combined-with-capecitabine-versus-gemcitabine-alone-as-first-line-chemotherapy-for-advanced-pancreatic-cancer-in-south-korea
#10
Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Ho Gak Kim, Myung Hwan Noh, Sang Hyub Lee, Yong-Tae Kim, Hyo Jung Kim, Chang Duck Kim, Dong Ki Lee, Kwang Bum Cho, Chang Min Cho, Jong Ho Moon, Dong Uk Kim, Dae Hwan Kang, Young Koog Cheon, Ho Soon Choi, Tae Hyeon Kim, Jae Kwang Kim, Jieun Moon, Hye Jung Shin, Si Young Song
BACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. METHODS: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in South Korea between 2007 and 2011. Patients were randomly assigned to receive GemCap (oral capecitabine 1660 mg/m plus Gem 1000 mg/m by 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break every 4 weeks) or Gem (by 30-minute intravenous infusion weekly for 3 weeks every 4 weeks)...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28070095/two-cases-of-unresectable-advanced-her2-positive-gastric-cancer-perforation-during-chemotherapy-with-trastuzumab
#11
Katsunori Matsueda, Tatsuya Toyokawa, Yuya Ueda, Shinya Endo, Masahiro Sakata, Isao Fujita, Jouichiro Horii, Takako Murakami
Case 1 was a 70-year-old man, and case 2 was a 65-year-old woman. Both were diagnosed with type 2 advanced HER2-positive gastric cancer. Capecitabine, cisplatin, and trastuzumab (HXP therapy) were administered to both patients. However, both patients developed peritonitis caused by gastric cancer perforation during HXP therapy on day 38 for case 1 and day 8 for case 2. Emergency omentum filling and gastric segmental resection were performed for both patients. The same chemotherapy regimen was continued after the surgery, and partial response was observed in both patients...
2017: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/28069070/successful-management-of-synchronous-recurrent-breast-carcinoma-with-chronic-myelogenous-leukemia-a-case-report
#12
Choukri Elm'hadi, Mohamed Reda Khmamouche, Rachid Tanz, Mehdi Toreis, ElMehdi Mahtat, Mohammed Allaoui, Mohammed Oukabli, Nezha Messaoudi, Hassan Errihani, Mohammed Ichou
BACKGROUND: Survival is increasing after early breast cancer revealing frequent relapses and possibility of developing secondary malignancies. The concomitant occurrence of these two events is exceptionally disastrous and lethal. We report a case of a Moroccan woman who was successfully managed for synchronous recurrent breast carcinoma and chronic myelogenous leukemia. CASE PRESENTATION: A 42-year-old Moroccan woman was diagnosed with localized breast carcinoma in 2008...
January 10, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28068240/does-unintentional-splenic-radiation-predict-outcomes-after-pancreatic-cancer-radiation-therapy
#13
Awalpreet S Chadha, Guan Liu, Hsiang-Chun Chen, Prajnan Das, Bruce D Minsky, Usama Mahmood, Marc E Delclos, Yelin Suh, Gabriel O Sawakuchi, Sam Beddar, Matthew H Katz, Jason B Fleming, Milind M Javle, Gauri R Varadhachary, Robert A Wolff, Christopher H Crane, Xuemei Wang, Howard Thames, Sunil Krishnan
PURPOSE: To determine whether severity of lymphopenia is dependent on radiation dose and fractional volume of spleen irradiated unintentionally during definitive chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC). METHODS: 177 patients with LAPC received induction chemotherapy (mainly gemcitabine-based regimens) followed by CRT (median 50.4 Gy with concurrent capecitabine) from January 2006 to December 2012. Absolute lymphocyte count (ALC) was recorded at baseline, before CRT, and 2 to 10 weeks after CRT...
February 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28067759/effective-synthesis-of-nucleosides-utilizing-o-acetyl-glycosyl-chlorides-as-glycosyl-donors-in-the-absence-of-catalyst-mechanism-revision-and-application-to-silyl-hilbert-johnson-reaction
#14
Chengyuan Liang, Weihui Ju, Shunjun Ding, Han Sun, Gennian Mao
An effective synthesis of nucleosides using glycosyl chlorides as glycosyl donors in the absence of Lewis acid has been developed. Glycosyl chlorides have been shown to be pivotal intermediates in the classical silyl-Hilbert-Johnson reaction. A possible mechanism that differs from the currently accepted mechanism advanced by Vorbrueggen has been proposed and verified by experiments. In practice, this catalyst-free method provides easy access to Capecitabine in high yield.
January 5, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28066869/a-case-report-stevens-johnson-syndrome-as-an-adverse-effect-of-capecitabine
#15
Priyanka Jadhav, Jane E Rogers, Rachna Shroff
No abstract text is available yet for this article.
January 9, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28045335/phase-ii-trial-of-capecitabine-plus-erlotinib-versus-capecitabine-alone-in-patients-with-advanced-colorectal-cancer
#16
Mark D Vincent, Daniel Breadner, Denis Soulieres, Ian G Kerr, Michael Sanatani, Walter Kocha, Peter Klimo, Mary J MacKenzie, Anne O'Connell, Frances Whiston, Anne S Malpage, Larry Stitt, Stephen A Welch
: Aim & methods: Capecitabine monotherapy as palliation for advanced colorectal cancer (CRC) is generally well tolerated. Adding erlotinib, an EGFR-tyrosine kinase inhibitor, might improve efficacy versus capecitabine alone. 82 patients received capecitabine alone (Arm 1) or capecitabine with erlotinib (Arm 2). RESULTS: Median time-to-progression (TTP) in Arm 1 was 7.9 months versus 9.2 in Arm 2. In KRAS-wild type (WT) patients TTP was 8.4 and 11.7 months in Arms 1 and 2, respectively...
January 3, 2017: Future Oncology
https://www.readbyqxmd.com/read/28040715/prolonged-response-to-her2-directed-therapy-in-a-patient-with-her2-amplified-rapidly-progressive-metastatic-colorectal-cancer
#17
Aparna Parikh, Chloe Atreya, W Michael Korn, Alan P Venook
HER2 gene amplifications and activating mutations in the HER2 receptor tyrosine kinase are present in 4% of metastatic colorectal cancers (mCRCs). HER2-targeted therapy is not standard of care, although preclinical and clinical data suggest that patients with HER2 amplifications and/or HER2-activating mutations may benefit from HER2-directed therapy. HER2 amplifications and activating mutations have also been implicated in resistance to anti-epidermal growth factor receptor-based therapy. This report describes a patient with KRAS, NRAS, and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline...
January 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28039597/vinorelbine-induced-perforation-of-a-metastatic-gastric-lesion
#18
REVIEW
W J Mullally, C B O'Súilleabháin, C Brady, S O'Reilly
BACKGROUND: Breast carcinoma metastasis to the gastrointestinal tract is rare and more frequently associated with lobular than ductal carcinoma (Borst and Ingold, Surg 114(4):637-641 [1]). The purpose of this article is to present a case based review of a unique gastrointestinal metastasis and literature review. METHODS: A 46 year old lady with metastatic invasive ductal breast cancer was admitted to A&E with sudden onset of epigastric and left shoulder pain. She completed the first cycle of capecitabine/vinorelbine 1 week previously...
December 30, 2016: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/28032528/chemotherapy-rechallenge-after-regorafenib-treatment-in-metastatic-colorectal-cancer-still-hope-after-the-last-hope
#19
Paola Bertocchi, Francesca Aroldi, Tiziana Prochilo, Fausto Meriggi, Giordano Domenico Beretta, Alberto Zaniboni
INTRODUCTION: The introduction of biological agents in cancer therapy is changing the progression of metastatic colorectal cancer. Currently, resistance to biological agents is an emerging problem; the progression of the disease is caused by the development of resistant clones. According to some authors, these clones can be re-sensitized to traditional and previously utilized chemotherapy agents. The results of the CORRECT study demonstrated the efficacy of regorafenib monotherapy in both KRAS wild type and mutant pretreated patients (pts)...
December 29, 2016: Journal of Chemotherapy
https://www.readbyqxmd.com/read/28028252/-chemotherapeutic-strategies-for-peritoneal-dissemination-of-gastric-cancer
#20
Tomohiro Matsushima, Takeru Wakatsuki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi
The prognosis of unresectable or metastatic gastric cancer is poor. One of the reasons for this is peritoneal dissemination, which is often observed in gastric cancer. Here, we discuss some new therapeutic strategies, especially chemotherapeutic strategies, for peritoneal dissemination of gastric cancer. Occasionally, in cases of peritoneal dissemination, patients have severe ascites or bowel obstruction. For those who have such complications, treatment via chemotherapy including S-1, capecitabine, or cisplatin is inappropriate...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
20530
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"